<code id='FAE0A83E1E'></code><style id='FAE0A83E1E'></style>

<acronym id='FAE0A83E1E'></acronym>

<center id='FAE0A83E1E'><center id='FAE0A83E1E'><tfoot id='FAE0A83E1E'></tfoot></center><abbr id='FAE0A83E1E'><dir id='FAE0A83E1E'><tfoot id='FAE0A83E1E'></tfoot><noframes id='FAE0A83E1E'>

<optgroup id='FAE0A83E1E'><strike id='FAE0A83E1E'><sup id='FAE0A83E1E'></sup></strike><code id='FAE0A83E1E'></code></optgroup>

<b id='FAE0A83E1E'><label id='FAE0A83E1E'><select id='FAE0A83E1E'><dt id='FAE0A83E1E'><span id='FAE0A83E1E'></span></dt></select></label></b><u id='FAE0A83E1E'></u>

~~<i id='FAE0A83E1E'><strike id='FAE0A83E1E'><tt id='FAE0A83E1E'><pre id='FAE0A83E1E'></pre></tt></strike></i>~~

Home» comprehensive» leisure time

leisure time

leisure time

author：knowledge 2025-09-29 23:20:03 Page View：652

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

advertisement

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Headspace, Meta partner to launch VR meditation app for Quest
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

leisure time

State Dept. review finds Biden bears some blame for Afghanistan failures

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

First medicine developed to treat MASH expected to be approved soon

First medicine developed to treat MASH expected to be approved soon

MadrigalCEOBillSiboldsaysthecompanyis"interestedinthepatientswhoaremostinneed."MadrigalPharmaceutica

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

House looks to weaken Medicare negotiation

TheHouseofRepresentativesishavingahearingontwobillsthatcouldweakenMedicare'sdrugpricenegotiationproc

read more